Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Day One Biopharmaceuticals reports robust Q3 earnings and eyes growth opportunities

Day One Biopharmaceuticals delivered strong Q3 earnings, showcasing commercial success and financial stability, with OJEMDA leading revenue generation.
Challenges lie in maintaining patient starts and addressing physician feedback, while opportunities in trials and partnerships offer avenues for growth and innovation.
Overall, Day One Biopharmaceuticals' performance reflects a promising trajectory with a solid foundation for future expansion and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program (CTEP) to expand therapeutic research opportunities using tovorafenib (DAY101). Under the terms of the CRADA, NCI investigators will have the opportunity to study tovorafenib in CTEP-sponsored trials to be conducted by NCI funded extramural clinical networks in several solid tumor and hematologic cancers based upon encouraging anti-tumor activity observed in previous studies.

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for Day One's lead investigational therapy, tovorafenib (DAY101). T

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors.

Day One Appoints Garry Nicholson as Chairman of the Board of Directors

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position.

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023

Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tuesday, August 9 at 10:55 a.m. ET.

Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet

Virtus LifeSci Biotech Clinical Trials ETF

Kezar Life Sciences Inc

Lyell Immunopharma

Mirati Therapeutics

Repare Therapeutics

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Biotech ETF Tops in June: 5 Stocks That Outperform

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters' option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share. All shares of common stock were offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $172.5 million.

Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Day One Biopharmaceuticals IPOed in May last year, raising $160m. Day One Biopharma's mission statement is to develop better pediatric cancer drugs.

Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case

A giant run-up on Monday could be the beginning of a much larger bull run.

Here's How Day One Biopharmaceuticals Stock Could Keep Climbing

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share. All shares of common stock are being offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 17, 2022, subject to the satisfaction of customary closing conditions.

Day One Announces Pricing of Upsized Public Offering of Common Stock

Day One Biopharmaceuticals (DAWN) stock is in the news Tuesday as a common stock offering has the company's shares moving. The post DAWN Stock Is in the Spotlight as Day One Announces Common Stock Offering appeared first on InvestorPlace.

DAWN Stock Is in the Spotlight as Day One Announces Common Stock Offering

Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?

Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?

Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. .

Why Day One Biopharma Shares Are Surging Today

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates among adolescents and adults Phase 1b/2 combination study, FIRELIGHT-1, to leverage insights from pediatric development to evaluate potential synergistic effects of the two candidates among adolescents and adults

Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors

Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022

Day One Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET.

Day One to Present at the 21st Annual Needham Virtual Healthcare Conference

Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022

Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 at 2:50 p.m. ET.

Day One to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DAY101 as a monotherapy in patients with RAF-altered solid tumors. DAY101 is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway.

Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022

Day One Reports Third Quarter 2021 Financial Results and Corporate Progress

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa Roberson as chief people officer. In her role, Ms. Roberson will oversee all aspects of Day One's human resources and talent acquisition efforts.

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Company's board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience.

News for Day One Biopharmaceuticals Stock (DAWN)